Absci Corporation, a clinical-stage biopharmaceutical company, has initiated a Phase 1 trial of ABS-101, its AI-designed antibody for inflammatory bowel disease (IBD). The drug is engineered for quarterly subcutaneous dosing and exhibits superior potency compared to existing anti-TL1A therapies. Interim data from the trial is expected in the latter half of 2025.
This clinical trial initiation is a significant milestone, not just for Absci, but potentially for the IBD treatment landscape. ABS-101’s design, facilitated by AI, aims to improve both efficacy and patient convenience through its enhanced potency and less frequent dosing schedule. This could lead to improved adherence and better outcomes for individuals living with IBD, a chronic condition impacting millions worldwide. Successful development of ABS-101 could offer a compelling alternative to current therapies, potentially setting a new standard for IBD management.
The Phase 1 trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of ABS-101 in approximately 40 healthy adult volunteers. Preclinical data suggests ABS-101 has high affinity and potency, reduced immunogenicity risk, and extended dosing intervals compared to competitors. Furthermore, preclinical studies indicate potential for improved bioavailability and prolonged target engagement.
The transition to a clinical-stage company and the advancement of ABS-101 signifies a tangible demonstration of Absci’s AI-driven drug creation platform. This success sets the stage for further development of their pipeline, including ABS-201 for androgenetic alopecia, and potentially solidifies their position as a leader in AI-powered drug discovery and development. The interim data expected in 2025 will be crucial for validating the platform’s capabilities and shaping the future direction of Absci’s programs. This success also has broader implications for the pharmaceutical industry, illustrating the potential of AI to accelerate drug development and potentially create more effective therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
